Considerations for routine clinical use. Since the U.S. Food and Drug Administration’s (FDA) approval of the first commercial systems in 2000, digital mammography has become an accepted standard of care in breast cancer screening and diagnosis and has paved the way for the newest groundbreaking technology in this arena - breast tomosynthesis (3D mammography).